Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington's disease

Behavioural Brain Research

Volumn 264, Issue , 2014, Pages 91-104

  Chakraborty, J ^a   Nthenge Ngumbau, D N ^a   Rajamma, U ^b   Mohanakumar, K P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b Manovikas Kendra Rehabilitation and Research Institute for the Handicapped   (India)

Author keywords

Cerebellar granular cell arborization; Dendritic spine damage; Gait abnormality; Glutamate; Striatal biogenic amine neurotransmitters

Indexed keywords

3 NITROPROPIONIC ACID; 4 AMINOBUTYRIC ACID; DOPAMINE; GLUTAMIC ACID; NEUROTRANSMITTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEAM BALANCING; BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN LEVEL; CEREBELLUM; CORPUS STRIATUM; DENDRITIC SPINE; GAIT; GRANULE CELL; HUNTINGTON CHOREA; LEARNING; MALE; MOTOR ACTIVITY; MOTOR COORDINATION; NERVE CELL LESION; NEUROANATOMY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; ROTAROD TEST; SWIMMING;

CEREBELLAR GRANULAR CELL ARBORIZATION; DENDRITIC SPINE DAMAGE; GAIT ABNORMALITY; GLUTAMATE; STRIATAL BIOGENIC AMINE NEUROTRANSMITTERS;

ANIMALS; CONVULSANTS; DENDRITIC SPINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUNTINGTON DISEASE; MALE; MELATONIN; MENTAL DISORDERS; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; NITRO COMPOUNDS; PROPIONATES; RATS; RATS, SPRAGUE-DAWLEY; SILVER STAINING; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 84896737304     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.01.048     Document Type: Article

References (71)

1. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
2. Subramaniam S., Sixt K.M., Barrow R., Snyder S.H. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009, 324:1327-1330.
3. Nekooki-Machida Y., Kurosawa M., Nukina N., Ito K., Oda T., Tanaka M. Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc Natl Acad Sci USA 2009, 106:9679-9684.
4. Pandey M., Borah A., Varghese M., Barman P.K., Mohanakumar K.P., Usha R. Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats. Neurochem Int 2009, 55:431-437.
5. Reynolds D.S., Carter R.J., Morton J.A. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J Neurosci 1998, 18:10116-10127.
6. Borah A., Mohanakumar K.P. l-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation. Neurochem Int 2010, 56:357-362.
7. Borah A., Mohanakumar K.P. Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. J Pineal Res 2009, 47:293-300.
8. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996, 39:385-389.
9. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997, 41:646-653.
10. Chakraborty J., Rajamma U., Mohanakumar K.P. A mitochondrial basis for Huntington's disease: therapeutic prospects. Mol Cell Biochem 2013, 10.1007/s11010-013-1951-9.
11. Orr A.L., Li S., Wang C.E., Li H., Wang J., Rong J., Xu X., Mastroberardino P.G., Greenamyre J.T., Li X.J. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci 2008, 2:2783-2792.
12. Wang H., Lim P.J., Karbowski M., Monteiro M.J. Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum Mol Genet 2009, 18:737-752.
13. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 2002, 5:731-736.
14. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993, 13:4181-4192.
15. Brouillet E., Jacquard C., Bizat N., Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 2005, 95:1521-1540.
16. Brouillet E., Jenkins B.G., Hyman B.T., Ferrante R.J., Kowall N.W., Srivastava R., Roy D.S., Rosen B.R., Beal M.F. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 1993, 60:356-359.
17. Pandey M., Varghese M., Sindhu K.M., Sreetama S., Navneet A.K., Mohanakumar K.P., Usha R. Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. J Neurochem 2008, 104:420-434.
18. Shear D.A., Dong J., Gundy C.D., Haik-Creguer K.L., Dunbar G.L. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry 1998, 22:1217-1240.
19. Nam E., Lee S.M., Koh S.E., Joo W.S., Maeng S., Im H.I., Kim Y.S. Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum. Brain Res 2005, 1046:90-96.
20. Thangarajan S., Deivasigamani A., Natarajan S.S., Krishnan P., Mohanan S.K. Neuroprotective activity of l-theanine on 3-nitropropionic acid induced neurotoxicity in rat striatum. Int J Neurosci 2014, 10.3109/00207454.2013.872642.
21. Mu S., OuYang L., Liu B., Zhu Y., Li K., Zhan M., Liu Z., Jia Y., Lei W. Protective effect of melatonin on 3-NP induced striatal interneuron injury in rats. Neurochem Int 2011, 59:224-234.
22. Tasset I., Medina F.J., Jimena I., Agüera E., Gascón F., Feijóo M., Sánchez-López F., Luque E., Peña J., Drucker-Colín R., Túnez I. Neuroprotective effects of extremely low-frequency electromagnetic fields on a Huntington's disease rat model: effects on neurotrophic factors and neuronal density. Neuroscience 2012, 209:54-63.
23. Kumar P., Kumar A. Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: possible role of nitric oxide. Behav Brain Res 2010, 206:38-46.
24. Kumar P., Kalonia H., Kumar A. Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity. Eur J Pharmacol 2012, 674:265-274.
25. Kumar P., Kalonia H., Kumar A. Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats: protective effect of licofelone. Br J Pharmacol 2011, 164:644-654.
26. Thakur T., Sharma S., Kumar K., Deshmukh R., Sharma P.L. Neuroprotective role of PDE4 and PDE5 inhibitors in 3-nitropropionic acid induced behavioural and biochemical toxicities in rats. Eur J Pharmacol 2013, 714:515-521.
27. Reiter R.J., Tan D.X., Manchester L.C., Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys 2001, 34:237-256.
28. Andrabi S.A., Sayeed I., Siemen D., Wolf G., Horn T.F. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J 2004, 18:869-871.
29. Luchetti F., Canonico B., Curci R., Battistelli M., Mannello F., Papa S., Tarzia G., Falcieri E. Melatonin prevents apoptosis induced by UV-B treatment in U937 cell line. J Pineal Res 2006, 40:158-167.
30. Tasset I., Espínola C., Medina F.J., Feijóo M., Ruiz C., Moreno E., Gómez M.M., Collado J.A., Muñoz C., Muntané J., Montilla P., Túnez I. Neuroprotective effect of carvedilol and melatonin on 3-nitropropionic acid-induced neurotoxicity in neuroblastoma. J Physiol Biochem 2009, 65:291-296.
31. Tasset I., Agüera E., Olmo-Camacho R., Escribano B., Sánchez-López F., Delgado M.J., Cruz A.H., Gascón F., Luque E., Peña J., Jimena I.M., Túnez I. Melatonin improves 3-nitropropionic acid induced behavioural alterations and neurotrophic factors levels. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1944-1949.
32. Wilhelm E.A., Ricardo J.C., Folharini B.C., Wayne N.C. Correlations between behavioural and oxidative parameters in a rat quinolinic acid model of Huntington's disease: protective effect of melatonin. Eur J Pharmacol 2013, 701:65-72.
33. Klapdor K., Dulfer G.B., Hammann A.F., Staay F.J.V. A low-cost method to analyse footprint patterns. J Neurosci Methods 1997, 75:49-54.
34. Chakraborty J., Singh R., Dutta D., Naskar A., Rajamma U., Mohanakumar K.P. Quercetin improves behavioural deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's disease. CNS Neurosci Ther 2014, 20:10-19.
35. Wang X.M., Gao X., Zhang X.H., Tu Y.Y., Jin M.L., Zhao G.P., Yu L., Jing N.H., Li B.M. The negative cell cycle regulator, Tob (transducer of ErbB-2), is involved in motor skill learning. Biochem Biophys Res Commun 2006, 24:1023-1027.
36. Haobam R., Sindhu K.M., Chandra G., Mohanakumar K.P. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Behav Brain Res 2005, 163:159-167.
37. Sengupta T., Mohanakumar K.P. 2-Phenylethylamine, a constituent of chocolate and wine, causes mitochondrial complex-I inhibition, generation of hydroxyl radicals and depletion of striatal biogenic amines leading to psycho-motor dysfunctions in Balb/c mice. Neurochem Int 2010, 57:637-646.
38. Vorhees C.V., Williams M.T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 2006, 1:848-858.
39. Muralikrishnan D., Mohanakumar K.P. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998, 12:905-912.
40. Rowley H.L., Martin K.F., Marsden C.A. Determination of in vivo amino acid neurotransmitters by high-performance liquid chromatography with o-phthalaldehyde-sulphite derivatisation. J Neurosci Methods 1995, 57:93-99.
41. Tripathy D., Haobam R., Nair R., Mohanakumar K.P. Engraftment of mouse embryonic stem cells differentiated by default leads to neuroprotection, behaviour revival and astrogliosis in parkinsonian rats. PLoS ONE 2013, 8:e72501.
42. Rao B.S.S., Desiraju T., Raju T.R. Neuronal plasticity induced by self-stimulation rewarding experience in rats-a study on alteration in dendritic branching in pyramidal neurons of hippocampus and motor cortex. Brain Res 1993, 627:216-224.
43. Rao B.S.S., Govindaiah T.R., Laxmi B.L.M., Raju T.R. Subicular lesions cause dendritic atrophy in CA1 and CA3 pyramidal neurons of the rat hippocampus. Neuroscience 2001, 102:319-327.
44. Naskar A., Manivasagam T., Chakraborty J., Singh R., Thomas B., Dhanasekaran M., Mohanakumar K.P. Melatonin synergizes with low doses of l-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism. J Pineal Res 2013, 55:304-312.
45. Túnez I., Montilla P., Del Carmen Muñoz M., Feijóo M., Salcedo M. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease. J Pineal Res 2004, 37:252-256.
46. Mehrotra A., Sandhir R. Mitochondrial cofactors in experimental Huntington's disease: Behavioural, biochemical and histological evaluation. Behav Brain Res 2014, 261:345-355.
47. Teunissen C.E., Steinbusch H.W., Angevaren M., Appels M., de Bruijn C., Prickaerts J., de Vente J. Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation. Neuroscience 2001, 105:153-167.
48. Takeuchi E., Sato Y., Miura E., Yamaura H., Yuzaki M., Yanagihara D. Characteristics of gait ataxia in δ2 glutamate receptor mutant mice, ho15J. PLoS ONE 2012, 7:e47553.
49. Tarsy D., Miyawaki E.K. Stiff-man syndrome. Report of a case. Arch Intern Med 1994, 154:1285-1288.
50. Dang M.T., Yokoi F., McNaught K.S., Jengelley T.A., Jackson T., Li J., Li Y. Generation and characterization of Dyt1 DeltaGAG knock-in mouse as a model for early-onset dystonia. Exp Neurol 2005, 196:452-463.
51. Detke M.J., Lucki I. Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Behav Brain Res 1996, 73:43-46.
52. Ferrante R.J., Kowall N.W., Richardson E.P. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J Neurosci 1991, 11:3877-3887.
53. Miller P.J., Zaborszky L. 3-Nitropropionic acid neurotoxicity: visualization by silver staining and implications for use as an animal model of Huntington's disease. Exp Neurol 1997, 146:212-229.
54. Sánchez-Carbente M.R., Massieu L. Transient inhibition of glutamate uptake in vivo induces neurodegeneration when energy metabolism is impaired. J Neurochem 1999, 72:129-138.
55. Liot G., Bossy B., Lubitz S., Kushnareva Y., Sejbuk N., Bossy-Wetzel E. Complex II inhibition by 3-NP causes mitochondrial fragmentation and neuronal cell death via an NMDA- and ROS-dependent pathway. Cell Death Differ 2009, 16:899-909.
56. Volbracht C., van Beek J., Zhu C., Blomgren K., Leist M. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur J Neurosci 2006, 23:2611-2622.
57. Tozzi A., Costa C., Di Filippo M., Tantucci M., Siliquini S., Belcastro V., Parnetti L., Picconi B., Calabresi P. Memantine reduces neuronal dysfunctions triggered by in vitro ischemia and 3-nitropropionic acid. Exp Neurol 2007, 207:218-226.
58. Karanian D.A., Baude A.S., Brown Q.B., Parsons C.G., Bahr B.A. 3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-d-aspartate receptor antagonism. Hippocampus 2006, 16:834-842.
59. Weller M., Paul S.M. 3-Nitropropionic acid is an indirect excitotoxin to cultured cerebellar granule neurons. Eur J Pharmacol 1993, 248:223-228.
60. Pedraza-Chaverrí J., Reyes-Fermín L.M., Nolasco-Amaya E.G., Orozco-Ibarra M., Medina-Campos O.N., González-Cuahutencos O., Rivero-Cruz I., Mata R. ROS scavenging capacity and neuroprotective effect of alpha-mangostin against 3-nitropropionic acid in cerebellar granule neurons. Exp Toxicol Pathol 2009, 61:491-501.
61. Martínez-Turrillas R., Puerta E., Chowdhury D., Marco S., Watanabe M., Aguirre N., Pérez-Otaño I. The NMDA receptor subunit GluN3A protects against 3-nitroproprionic-induced striatal lesions via inhibition of calpain activation. Neurobiol Dis 2012, 48:290-298.
62. La Fontaine M.A., Geddes J.W., Banks A., Butterfield D.A. 3-Nitropropionic acid induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease. Brain Res 2000, 858:356-362.
63. Behrens M.I., Koh J., Canzoniero L.M., Sensi S.L., Csernansky C.A., Choi D.W. 3-Nitropropionic acid induces apoptosis in cultured striatal and cortical neurons. Neuroreport 1995, 6:545-548.
64. Petrosillo G., Fattoretti P., Matera M., Ruggiero F.M., Bertoni-Freddari C., Paradies G. Melatonin prevents age-related mitochondrial dysfunction in rat brain via cardiolipin protection. Rejuvenation Res 2008, 11:935-943.
65. Dragicevic N., Copes N., O'Neal-Moffitt G., Jin J., Buzzeo R., Mamcarz M., Tan J., Cao C., Olcese J.M., Arendash G.W., Bradshaw P.C. Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling. J Pineal Res 2011, 51:75-86.
66. Chen H.Y., Hung Y.C., Chen T.Y., Huang S.Y., Wang Y.H., Lee W.T., Wu T.S., Lee E.J. Melatonin improves presynaptic protein, SNAP-25, expression and dendritic spine density and enhances functional and electrophysiological recovery following transient focal cerebral ischemia in rats. J Pineal Res 2009, 47:260-270.
67. Galliano E., Gao Z., Schonewille M., Todorov B., Simons E., Pop A.S., D'Angelo E., van den Maagdenberg A.M., Hoebeek F.E., De Zeeuw C.I. Silencing the majority of cerebellar granule cells uncovers their essential role in motor learning and consolidation. Cell Rep 2013, 3:1239-1251.
68. Garcia B.G., Neely M.D., Deutch A.Y. Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss. Cereb Cortex 2010, 20:2423-2432.
69. Selden L.A., Kinosian H.J., Estes J.E., Gershman L.C. Impact of profilin on actin-bound nucleotide exchange and actin polymerization dynamics. Biochemistry 1999, 38:2769-2778.
70. Kovar D.R., Harris E.S., Mahaffy R., Higgs H.N., Pollard T.D. Control of the assembly of ATP- and ADP-actin by formins and profilin. Cell 2006, 124:423-435.
71. Romero S., Didry D., Larquet E., Boisset N., Pantaloni D., Carlier M.F. How ATP hydrolysis controls filament assembly from profilin-actin: implication for formin processivity. J Biol Chem 2007, 282:8435-8445.